{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002015741,0.0008465023,0.003387992,0.0001268728,0.0004735669,0.0002302109,0.002290241,0.0007596834,0.0004096374],"category_scores_gemma":[0.006604707,0.0006313731,0.0004215971,0.0008043686,0.0006079522,0.0002566303,0.0009962927,0.0009958685,0.000567469],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.4978594,"about_ca_system_score_gemma":0.2760753,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01265212,"about_ca_topic_score_gemma":0.002069114,"domain_scores_codex":[0.9924024,0.001011216,0.001725174,0.00171813,0.0009386097,0.0022045],"domain_scores_gemma":[0.9896625,0.006108528,0.0008142917,0.002057587,0.000434615,0.0009225249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9329637,0.0001035194,1.981741e-7,0.0003114744,0.001320626,0.0007789631,0.003773261,0.005083232,0.00146957,0.0000972011,0.04900737,0.005090915],"study_design_scores_gemma":[0.5743297,0.01299803,3.792801e-7,0.0001703181,0.00108105,0.00006721642,0.0002521997,0.338947,0.001047077,0.00005175523,0.07068523,0.0003700723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9568092,0.003390255,0.0003179706,0.00386397,0.003487822,0.02547128,0.001061138,0.000522562,0.005075778],"genre_scores_gemma":[0.9764201,0.00162171,0.001293841,0.003023563,0.008690153,0.003311826,0.002247887,0.0002591708,0.003131734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.358634,"threshold_uncertainty_score":0.9996138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2241489103395237,"score_gpt":0.4279868705273332,"score_spread":0.2038379601878094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}